Why Kidney Diets Must Be Individualized for Chronic Kidney Disease
Year: 2026
Type: article
Abstract: Deep-research Food-as-Medicine article on chronic kidney disease, asking why kidney diets must be individualized rather than copied from a single diet sheet. CDC Chronic Kidney Disease in the United States, 2023 (via NIDDK, verified live 2026-11-09) estimates CKD in 35.5 million U.S. adults (14%), in about 20% of non-Hispanic Black adults versus about 12% of non-Hispanic White adults, with more than 808,000 people living with end-stage kidney disease (USRDS 2023). The 2020 KDOQI nutrition guideline (Ikizler 2020, PMID 32829751) organizes kidney nutrition as dietitian-delivered medical nutrition therapy across stages 1-5, dialysis, and transplant; its expert commentary (Kistler 2021, PMID 32737016) states protein ranges of 0.55-0.6 g/kg/day without diabetes and 0.6-0.8 g/kg/day with diabetic kidney disease. In non-diabetic CKD, a Cochrane synthesis of 17 trials (n=2,996; Hahn 2020, PMID 33118160) found low protein (0.5-0.6 g/kg/day) made little difference to reaching end-stage kidney disease versus normal protein (RR 1.05, 95% CI 0.73-1.53), while very low protein (0.3-0.4 g/kg/day) probably reduced progression in advanced disease (RR 0.65, 95% CI 0.49-0.85), with harms and quality of life barely measured. Salt reduction in CKD lowered blood pressure by -6.91/-3.91 mm Hg with high certainty across 21 studies (McMahon 2021, PMID 34164803), and by 10/4 mm Hg in a 20-person crossover trial (McMahon 2013, PMID 24204003), while also increasing symptomatic hypotension (RR 6.70). A plant-dominant low-protein framework (0.6-0.8 g/kg/day, >50% plant sources; Kalantar-Zadeh 2020, PMID 32610641) is presented as a framework, not a trial result, and a potassium literature review (AlSahow 2023, PMID 37766841) found a lack of strong evidence for intense potassium restriction and recommended individualized, gradual, stepwise reduction. No product is named or recommended; kidney disease gives no supplement recommendation without clinician or pharmacist review. Evidence grade: MODERATE. Educational article from the Buddha Ayurvedic School of Medicine: https://buddha.hospital
Author: Shu, Ajarn Shaman
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225619757
FWCI:
Cites:
Cited by:
Related to: